CHECK OUT OUR 2026 VENTURE REPORT

Portal's Sr. Director of Venture, Michael Schultz released his 2026 venture report that outlines reasons for optimism while also discussing potential obstacles. 

• Signs of market recovery, including improving public biotech performance and renewed generalist investor participation
• Falling interest rates and shifting capital allocation trends that may benefit life sciences
• A resurgence in pharmaM&A, with 35 transactions over $1 billion in the past

If you're interested in reading the full report, submit the form below and we'll email you a copy of the venture report directly.